BUMPy: A Model-Independent Tool for Constructing Lipid Bilayers of Varying Curvature and Composition.
Journal of Chemical Theory and Computation.
click
Understanding Conformational Dynamics of Complex Lipid Mixtures Relevant to Biology.
J Membrane Biol
click
Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity.
eLife
click
Stem cells and heterotopic ossification: lessons from animal models.
Bone
click
Low-Level Antimicrobials in the Medicinal Leech Select for Resistant Pathogens That Spread to Patients.
mBio
click
Early-life antibiotics attenuate regulatory T cell generation and increase the severity of murine house dust mite-induced asthma.
Pediatric Research
click
Catalytic Domains in RNA-Binding Proteins.
In Roberts G., Watts A., European Biophysical Societies (eds.) Encyclopedia of Biophysics. Springer, Berlin, Heidelberg.
click
Defining microbiome function.
Nature Microbiology
click
Factors influencing bacterial microbiome composition in a wild non-human primate community in Taï National Park, Côte d’Ivoire.
The ISME Journal (2018)
click
Characterizing the DNA Methyltransferases of Haloferax volcanii via Bioinformatics, Gene Deletion, and SMRT Sequencing.
Gene- Section: Microbial Genetics and Genomics, Genetic and Genomics Extremophiles
click
Comparative Analysis of Surface Layer Glycoproteins and Genes Involved in Protein Glycosylation in the Genus Haloferax.
Gene- Section: Microbial Genetics and Genomics, Genetic and Genomics Extremophiles
click
For a full list of publications,
click
MCB Welcomed Dr. Raja Jothi, from NIH, at this year’s Khairallah SymposiumTuesday, October 23rd, Dr. Raja Jothi, Senior Investigator and Chief, Systems Biology Section, NIEHS, NIH presented his talk entitled “Uncovering Unknown Unknowns of Gene Regulation," made possible by The Dr. Edward A. Khairallah and Dr. Lamia H. Khairallah Fund for Scholarship.
Biohaven Pharmaceutical Company acquires an option to license an anti-metallothionein antibody from Michael Lynes for the treatment of inflammatory and autoimmune diseases.This investment will develop the potential therapeutic applications that Dr. Lynes, his MCB lab group, and collaborators at the University of Gent and Joslin Diabetes Center have been working to elucidate.
